Nanospectra Biosciences is a privately-held medical device company, pioneering the patient-centric use of nanomedicine for selective thermal ablation. AuroLase, the company's lead product, is the first ultra-focal therapy for prostate cancer. Nanospectra's ultra-focal approach maximizes treatment efficacy while minimizing side effects associated with current treatments, including surgery, radiation, and alternative focal therapies. Implementing a multi-prong growth strategy, Nanospectra is focusing on clinical advancements, exclusive partnering agreements and ongoing research and development. Nanospectra's technology development has been funded to date by a series of grants, private equity investments and corporate partnerships.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/08/20 | $3,000,000 | Series B-1 |
Sirtex Medical | undisclosed |
